⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097631 | 0.81 | CYP2C9 (0.32) | — | |
| SCHEMBL9098438 | 0.77 | GRIN2D (0.33) | — | |
| SCHEMBL9095038 | 0.74 | — | — | |
| SCHEMBL9046094 | 0.71 | ADORA2A (0.33) | — | |
| SCHEMBL9048189 | 0.71 | — | — | |
| SCHEMBL9047746 | 0.71 | L3MBTL1 (0.37) | — | |
| SCHEMBL9047832 | 0.71 | HRH3 (0.33) | — | |
| SCHEMBL9047634 | 0.70 | DRD3 (0.35) | — | |
| SCHEMBL9048002 | 0.70 | HRH4 (0.35) | — | |
| SCHEMBL9049366 | 0.69 | HRH4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347166-A1 | Schizophrenic Disorder Treatment using Combination Therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2022-11-03 | — | — | US | claimed |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20220347166-A1 | Schizophrenic Disorder Treatment using Combination Therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2022-11-03 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2008011016-A2 | TREATING GASTROESOPHAGEAL REFLUX DISEASE WITH 5-HT3- AND GABA RECEPTOR AGONISTS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005021040-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |